Alzheimer’s disease market expected to reach $14B globally in 2030
filadendron/E+ via Getty Images
Driven by novel therapeutics from Biogen (NASDAQ:BIIB)/ Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY), the Alzheimerâs disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said last week.
That implies a compound annual growth rate of 20% from 2020 when the AD market size was $2.2B, the research firm projected considering the U.S., U.K., France, Germany, Italy, Spain, Japan, and China in its forecast.
The introduction of 23 new pipeline products, including disease-modifying therapies (DMTs), is expected to be behind this momentum, GlobalData said in its report titled âAlzheimerâs Disease: Eight-Market Drug Forecast and Market Analysis â Update.â
Before 2021, the AD market was dominated by acetylcholinesterase inhibitors designed to relieve Alzheimerâs symptoms. âThese drugs are modestly effective and primarily off patent, thus creating significant opportunity for new entrants into the AD market,â remarked Philippa Salter, Neurology Analyst at GlobalData.
Recently, drug developers have seen success with amyloid targeting Alzheimerâs agents. The FDA approved the first DMT Aduhelm (aducanumab), an anti-amyloid monoclonal antibody (mAb) from Biogen (BIIB)/ Eisai (OTCPK:ESAIY), in 2021, albeit under controversial circumstances.
This week, an advisory panel of the agency overwhelmingly endorsed the full approval for the duoâs new anti-amyloid agent Leqembi (lecanemab) following accelerated approval early this year. A shift to its full approval expected within weeks could pave the for its Medicare coverage under certain restrictions.
The market rollout of Aduhelm, Leqembi, and Eli Lillyâs (LLY) upcoming anti-amyloid mAbs donanemab and remternetug will likely be a significant factor behind the AD market growth. 
However, sales for Aduhelm are expected to be low. âThe drugâs launch was marred by controversy surrounding the FDAâs decision, which conflicted with its advisory boardâs opinion that there was not enough evidence to support whether Aduhelm could effectively slow cognitive decline,â Salter noted.
In contrast, Leqembi and donanemab, for which Lilly (LLY) intends to file a marketing application for regular approval this quarter, are set to become top-selling AD drugs by 2030, generating $3.5B and $2.0B in sales, respectively.
âLeqembi and donanemab have both demonstrated that they can reduce cognitive decline in Phase III clinical trials,â Salter explained.
However, there will be challenges to treatment uptake, including low diagnosis rates across the disease spectrum. As a result, there will be an unmet need for accurate, convenient diagnostic tests and biomarkers used for patient classification and the evaluation of therapeutic response.
âAs trial designs and the incorporation of biomarkers in trials improve, and testing in the pre-symptomatic AD population becomes accessible, opportunity will increase for players looking to enter the AD market in the future,â Salter concluded.
Other Alzheimer's drug developers: Cassava Sciences (SAVA), Anavex Life Sciences (AVXL), Annovis Bio (ANVS), Alnylam Pharma (ALNY), Prothena (PRTA), Alector (ALEC), AC Immune (ACIU), INmune Bio (INMB), Athira Pharma (ATHA), BioVie (BIVI) and Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF), Acumen Pharma (ABOS)
More on AD players

Biogenâs new Alzheimerâs drug to raise annual Medicare costs by up to $5B â study
Eisai: Potentially The Best Bet On The Alzheimer's Treatment Market
Anavex's Blarcamesine: Sigma-1 Receptor Agonists And Antioxidants For Alzheimer's Disease
Lilly's New Donanemab Data For Alzheimer's